CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Zacks Investment Research on MSN
Why is CRISPR Therapeutics (CRSP) up 3.3% since last earnings report?
It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 3.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...
Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...
Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...
When Victoria Gray was still a baby, she started howling so inconsolably during a bath that she was rushed to the emergency room. The diagnosis was sickle-cell disease, a genetic condition that causes ...
CRISPR is in the process of a BLA for a potential breakthrough drug. The company isn't profitable and is losing its chief operating officer. CRISPR has more than $1.9 billion in cash. It opened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback